Indication
Synergy for group B streptococcal septicemia
The phrase "synergy for group B streptococcal septicemia" denotes an adjunctive antimicrobial therapeutic strategy rather than a discrete medical condition. Read more about Synergy for group B streptococcal septicemia
12 drugs 11 manufacturers
Drugs that treat it
Common Synergy for group B streptococcal septicemia therapies.
GENTAMICIN IN NACL (ISO-OSM) (gentamicin sulfate in sodium chloride, iso-osmotic)
GENTAMICIN SULFATE (gentamicin sulfate/PF)
GENTAMICIN SULFATE (gentamicin sulfate/PF)
GENTAMICIN SULFATE IN NS (gentamicin sulfate in sodium chloride, iso-osmotic)
GENTAMICIN SULFATE (gentamicin sulfate/PF)
GENTAMICIN SULFATE
GENTAMICIN SULFATE (gentamicin sulfate/PF)
GENTAMICIN SULFATE (gentamicin sulfate/PF)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonThe phrase "synergy for group B streptococcal septicemia" denotes an adjunctive antimicrobial therapeutic strategy rather than a discrete medical condition.
The underlying disease is septicemia caused by *Streptococcus agalactiae* (group B *Streptococcus*), a severe, systemic bloodstream infection that predominantly affects neonates—manifesting as early-onset or late-onset neonatal sepsis—as well as pregnant women, elderly individuals, and immunocompromised adults.
Pathophysiologically, bacterial invasion into the intravascular space elicits a dysregulated host inflammatory cascade characterized by hemodynamic instability, temperature dysregulation, respiratory distress, and potential multi-organ dysfunction.
In this context, antimicrobial synergy describes the co-administration of an aminoglycoside alongside a cell-wall-active beta-lactam to accelerate bactericidal clearance from the bloodstream during the initial, critical phase of invasive systemic infection.
- nih.gov
The phrase "synergy for group B streptococcal septicemia" denotes an adjunctive antimicrobial therapeutic strategy rather than a discrete medical condition In this context, antimicrobial synergy describes the co-administration of an aminoglycoside alongside a cell-wall-active beta-lactam to accelerate bactericidal clearance from the bloodstream during the initial, critical phase of invasive systemic infection
- aap.org
The phrase "synergy for group B streptococcal septicemia" denotes an adjunctive antimicrobial therapeutic strategy rather than a discrete medical condition In this context, antimicrobial synergy describes the co-administration of an aminoglycoside alongside a cell-wall-active beta-lactam to accelerate bactericidal clearance from the bloodstream during the initial, critical phase of invasive systemic infection
- science.gov
The underlying disease is septicemia caused by *Streptococcus agalactiae* (group B *Streptococcus*), a severe, systemic bloodstream infection that predominantly affects neonates—manifesting as early-onset or late-onset neonatal sepsis—as well as pregnant women, elderly individuals, and immunocompromised adults
- who.int
The underlying disease is septicemia caused by *Streptococcus agalactiae* (group B *Streptococcus*), a severe, systemic bloodstream infection that predominantly affects neonates—manifesting as early-onset or late-onset neonatal sepsis—as well as pregnant women, elderly individuals, and immunocompromised adults
- nih.gov
The underlying disease is septicemia caused by *Streptococcus agalactiae* (group B *Streptococcus*), a severe, systemic bloodstream infection that predominantly affects neonates—manifesting as early-onset or late-onset neonatal sepsis—as well as pregnant women, elderly individuals, and immunocompromised adults Pathophysiologically, bacterial invasion into the intravascular space elicits a dysregulated host inflammatory cascade characterized by hemodynamic instability, temperature dysregulation, ...
- researchgate.net
Pathophysiologically, bacterial invasion into the intravascular space elicits a dysregulated host inflammatory cascade characterized by hemodynamic instability, temperature dysregulation, respiratory distress, and potential multi-organ dysfunction
Personalize your experience
Follow Synergy for group B streptococcal septicemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.